Novartis Leukemia Treatment Yields High Remission Rate
This article is for subscribers only.
A new leukemia immune treatment being developed by Novartis AG led to the disappearance of cancer in 90 percent of patients, a study showed.
The therapy, a process that involved taking a patient’s T cells and reprogramming them to hunt cancer cells, resulted in complete remission of 27 of 30 patients with acute lymphoblastic leukemia, a deadly pediatric cancer, according to the study published today by the New England Journal of Medicine.